CDP 870: Phase II results in rheumatoid arthritis
Efficacy fully competitive at 400 mg monthly
- very rapid onset - 75% achieving ACR20 reach it after 7 days
Excellent safety profile
- no statistical differences between 400 mg and placebo adverse events
- no increased injection site reactions or URT infection
- ~ 600 patients treated with CDP 870 (all studies)
Pharmacia initiating Ph III studies